Chet Oon

Chet Oon

Auto-generated profile, based on publicly available information

Chet Oon

Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JAJaime Abrego
Jaime Abrego
HSHannah Sanford-Crane
Hannah Sanford-Crane
COChet Oon
Chet Oon
XXXu Xiao
Xu Xiao
CBCourtney B. Betts
Courtney B. Betts
MSMara Sherman
Mara Sherman
Despite significant recent advances in precision medicine, pancreatic ductal adenocarcinoma (PDAC) remains near uniformly lethal. Although immune-modulatory therapies hold promise to meaningfully improve outcomes for patients with PDAC, the development of such therapies requires an improved understanding of the immune evasion mechanisms that characterize the PDAC microenvironment. Here, we show that cancer cell–intrinsic glutamic-oxaloacetic transaminase 2 (GOT2) shapes the immune microenvironment to suppress antitumor immunity. Mechanistically, we find that GOT2 functions beyond its established role in the malate–aspartate shuttle and promotes the transcriptional activity of nuclear receptor peroxisome proliferator–activated receptor delta (PPARδ), facilitated by direct fatty acid binding. Although GOT2 is dispensable for cancer cell proliferation in vivo, the GOT2–PPARδ axis promotes spatial restriction of both CD4+ and CD8+ T cells from the tumor microenvironment. Our results demonstrate a noncanonical function for an established mitochondrial enzyme in transcriptional regulation of immune evasion, which may be exploitable to promote a productive antitumor immune response. Significance: Prior studies demonstrate the important moonlighting functions of metabolic enzymes in cancer. We find that the mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear receptor PPARδ, and this functional interaction critically regulates the immune microenvironment of pancreatic cancer to promote tumor progression. See related commentary by Nwosu and di Magliano, p. 2237.. This article is highlighted in the In This Issue feature, p. 2221

10 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
MOMaria Kathrina Oñate
Maria Kathrina Oñate
COChet Oon
Chet Oon
SBSohinee Bhattacharyya
Sohinee Bhattacharyya
VLVivien Low
Vivien Low
CCCanping Chen
Canping Chen
MSMara Sherman
Mara Sherman
Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to immune and nonimmune stromal elements enable loss of homeostasis during tumor onset. The precise mechanisms by which normal stromal cell states limit tissue plasticity and tumorigenesis, and which are lost during tumor progression, remain largely unknown. In this study, we show that healthy pancreatic mesenchyme expresses the paracrine signaling molecule KITL, also known as stem cell factor, and identify the loss of stromal KITL during tumorigenesis as tumor promoting. Genetic inhibition of mesenchymal KITL in the contexts of health, injury, and cancer together indicates a role for KITL signaling in the maintenance of pancreas tissue architecture, such that the loss of the stromal KITL pool increased tumor growth and reduced survival of tumor-bearing mice. Together, these findings implicate the loss of mesenchymal KITL as a mechanism for establishing a tumor-permissive microenvironment. Significance: By analyzing transcriptional programs in healthy and tumor-associated pancreatic mesenchyme, we find that a subpopulation of mesenchymal cells in healthy pancreas tissue expresses the paracrine signaling factor KITL. The loss of mesenchymal KITL is an accompanying and permissive feature of pancreas tumor evolution, with potential implications for cancer interception. See related article by Dolskii and Cukierman, p. 872

2 May 2025
Verified
Other
Open access
PDF file
MOMaria Kathrina Oñate
Maria Kathrina Oñate
COChet Oon
Chet Oon
SBSohinee Bhattacharyya
Sohinee Bhattacharyya
VLVivien Low
Vivien Low
CCCanping Chen
Canping Chen
MSMara Sherman
Mara Sherman
Supplementary Figure S2: Kitl is expressed by healthy pancreatic mesenchyme and reduced upon activation to a CAF phenotype

2 May 2025
Verified
Other
Open access
PDF file
MOMaria Kathrina Oñate
Maria Kathrina Oñate
COChet Oon
Chet Oon
SBSohinee Bhattacharyya
Sohinee Bhattacharyya
VLVivien Low
Vivien Low
CCCanping Chen
Canping Chen
MSMara Sherman
Mara Sherman
Supplementary Figure S1: scRNA-seq reveals gene expression programs in PSCs and PSC-derived CAFs

2 May 2025
Verified
Other
Open access
PDF file
MOMaria Kathrina Oñate
Maria Kathrina Oñate
COChet Oon
Chet Oon
SBSohinee Bhattacharyya
Sohinee Bhattacharyya
VLVivien Low
Vivien Low
CCCanping Chen
Canping Chen
MSMara Sherman
Mara Sherman
Supplementary Figure S3: Stromal KITL promotes regulation of pancreas tissue architecture

17 June 2026
Verified
Other
Open access
MOMaria Kathrina Oñate
Maria Kathrina Oñate
COChet Oon
Chet Oon
SBSohinee Bhattacharyya
Sohinee Bhattacharyya
VLVivien Low
Vivien Low
CCCanping Chen
Canping Chen
MSMara Sherman
Mara Sherman
Supplementary Figure S2: Kitl is expressed by healthy pancreatic mesenchyme and reduced upon activation to a CAF phenotype